Table 4.
Factors affecting PFS and OS by multivariate Cox’s proportional hazards regression analysis.
| Items | PFS | OS | ||
|---|---|---|---|---|
| P-value | HR (95% CI) | P-value | HR (95% CI) | |
| Vascular invasion (yes vs. no) | 0.147 | 1.775 (0.818–3.852) | 0.001 | 9.030 (2.355–34.629) |
| Higher CNLC stage | 0.950 | 1.016 (0.619–1.667) | 0.384 | 1.478 (0.613–3.560) |
| AFP (≥400 ng/ml vs. <400 ng/ml) | 0.274 | 0.638 (0.285–1.427) | 0.079 | 2.636 (0.895–7.762) |
| More times of previous TACE | 0.389 | 0.851 (0.590–1.228) | 0.018 | 1.618 (1.088–2.407) |
| More times of TACE | 0.377 | 0.645 (0.243–1.708) | 0.107 | 0.233 (0.040–1.368) |
| More cycles of camrelizumab | 0.002 | 0.415 (0.240–0.718) | 0.070 | 0.484 (0.220–1.062) |
| Longer interval between TACE and camrelizumab administration | 0.032 | 1.873 (1.056–3.322) | 0.097 | 1.811 (0.898–3.654) |
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; CNLC, China liver cancer; AFP, alpha-fetoprotein; TACE, transarterial chemoembolization. The bold values indicate the comparison with statistical significance.